GSK-3α/β and MEK inhibitors assist the microenvironment of tumor initiation

Area of Science:

• Stem Cell Biology
• Cancer Research
• Personalized Medicine

Background:

• Induced pluripotent stem cells (iPSCs) are valuable for disease modeling and personalized medicine.
• Current methods for generating cancer stem cells (CSCs) from iPSCs using conditioned medium (CM) have limitations in efficiency.
• Mimicking the tumor microenvironment is crucial for effective CSC generation.

Purpose of the Study:

• To develop an efficient method for converting normal human stem cells into CSCs.
• To establish novel personalized cancer models for research and therapeutic screening.
• To investigate the role of specific inhibitors and CM in CSC differentiation.

Main Methods:

• Human iPSCs, reprogrammed from monocytes, were cultured with 50% pancreatic cancer cell-derived CM.
• The culture medium was supplemented with a MEK inhibitor (AZD6244) and a GSK-3α/β inhibitor (CHIR99021).
• Converted cells were assessed for CSC characteristics in vitro and in vivo, including gene expression analysis.

Main Results:

• The combined treatment successfully converted human iPSCs into cells exhibiting CSC phenotypes.
• Converted cells demonstrated self-renewal, differentiation capabilities, and malignant tumorigenicity in vivo.
• Primary cultures of tumors from converted cells showed elevated expression of CSC markers (CD44, CD24, EPCAM) and maintained stemness genes.

Conclusions:

• Inhibition of GSK-3α/β and MEK, alongside a tumor microenvironment mimicry using CM, can effectively convert normal stem cells into CSCs.
• This approach offers a promising strategy for establishing personalized cancer models.
• These models can facilitate the investigation of tumor initiation and the screening of personalized therapies targeting CSCs.